Revvity (NYSE:RVTY) Posts Earnings Results, Beats Expectations By $0.20 EPS

Posted by Francis Steltz on Aug 4th, 2026

Revvity (NYSE:RVTY – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.21 by $0.20, Zacks reports. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The company’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.18 earnings per share. Revvity updated its FY 2026 guidance to 5.300-5.400 EPS.

Here are the key takeaways from Revvity’s conference call:

Revvity reported Q2 revenue of $711 million, 3% pro forma organic growth, and adjusted EPS of $1.41, exceeding expectations. Performance benefited from stronger operations, favorable tax timing, and $16 million in tariff refunds.
The company raised its 2026 outlook to 4%–5% organic growth, approximately 28.7% adjusted operating margin, and adjusted EPS of $5.30–$5.40. Management said the guidance assumes continued improvement in pharma and biotech spending but no further acceleration beyond current trends.
Diagnostics remained a major strength, growing 11% organically, with reproductive health up in the mid-teens and Immunodiagnostics outside China accelerating to high-single-digit growth. Newborn screening and the Genomics England sequencing contract continued to support results.
AI-related demand is driving increased orders for high-content screening instruments, particularly the Opera Phenix OptIQ, with double-digit growth and backlog exceeding near-term production capacity. Management expects subsequent reagent pull-through as customers expand their lab-in-the-loop workflows.
Signals software revenue declined approximately 20% year over year because of contract timing and difficult comparisons, although annualized portfolio value and ARR continued to grow strongly. Management expects a return to double-digit organic growth in the second half, making the recovery dependent on renewals and adoption of new AI-enabled offerings.

Revvity Stock Performance

RVTY stock traded down $4.38 during midday trading on Tuesday, hitting $110.84. 837,698 shares of the company traded hands, compared to its average volume of 1,376,879. Revvity has a twelve month low of $81.22 and a twelve month high of $118.30. The company has a quick ratio of 1.41, a current ratio of 1.72 and a debt-to-equity ratio of 0.37. The business has a 50 day simple moving average of $106.88 and a 200-day simple moving average of $99.92. The stock has a market capitalization of $12.37 billion, a price-to-earnings ratio of 53.12, a price-to-earnings-growth ratio of 2.21 and a beta of 1.07.

Revvity Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date is Friday, October 23rd. Revvity’s dividend payout ratio (DPR) is 13.40%.

Institutional Trading of Revvity

Institutional investors and hedge funds have recently modified their holdings of the company. Pacer Advisors Inc. boosted its holdings in shares of Revvity by 4.7% during the 4th quarter. Pacer Advisors Inc. now owns 11,152 shares of the company’s stock worth $1,079,000 after buying an additional 504 shares during the period. Virtu Financial LLC bought a new position in Revvity in the 4th quarter worth $384,000. Corient Private Wealth LLC raised its holdings in Revvity by 985.8% in the 4th quarter. Corient Private Wealth LLC now owns 126,664 shares of the company’s stock worth $12,245,000 after acquiring an additional 114,999 shares during the period. Alberta Investment Management Corp bought a new position in Revvity in the 4th quarter worth $1,442,000. Finally, Mercer Global Advisors Inc. ADV lifted its position in Revvity by 10.4% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 15,656 shares of the company’s stock worth $1,515,000 after acquiring an additional 1,480 shares during the last quarter. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

RVTY has been the topic of a number of research reports. JPMorgan Chase & Co. dropped their price objective on Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Wall Street Zen downgraded shares of Revvity from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Wolfe Research began coverage on shares of Revvity in a research note on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Evercore restated an “outperform” rating and set a $125.00 price target on shares of Revvity in a report on Monday, July 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Revvity in a research note on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Revvity presently has an average rating of “Hold” and a consensus price target of $108.36.

Get Our Latest Stock Analysis on RVTY

Revvity Company Profile

(Get Free Report)

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.